SGS is pleased to announce the acquisition of Vitrology Limited based in Glasgow, UK.
Vitrology is a biopharmaceutical contract testing organization and a dynamic force in the biosafety testing sector of the pharmaceutical industry.
At its state-of-the-art GLP / cGMP (Good Laboratory Practices / current Good Manufacturing Practices) laboratory facility, Vitrology provides a comprehensive range of biosafety services such as virology, cell and molecular biology as well as microbiology and electron microscopy.
Founded in 2007, privately owned and backed by Archangel Informal Investment, Vitrology has 38 employees with sales agents in North America and Asia. In 2011, it generated revenue in excess of £3 million.
“Building upon our biologic therapeutics strategy and following our recent successful M-Scan acquisition, Vitrology now complements the services provided by SGS. We are now among the top global players. It creates an ideal platform for further deployment in virology and molecular biology, to be leveraged within our Life Science global network” said Chris Kirk, CEO of SGS.
For further information, please contact:
Jean-Luc de Buman
Communications & IR
1 place des Alpes
CH - 1211 Geneva 1
t: (+41-22) 739 91 11
f: (+41-22) 739 92 00
SGS is the world’s leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With more than 70,000 employees, SGS operates a network of over 1,350 offices and laboratories around the world.